Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 230 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: N Acetyl Cysteine Clear all

Conditions: Methamphetamine Dependence
Interventions: Naltrexone plus N-Acetyl Cysteine, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bipolar Disorder, Bipolar Depression
Interventions: N-acetylcysteine, Minocycline, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ulcerative Colitis, Left-sided Ulcerative Colitis, Distal Ulcerative Colitis
Interventions: Zoenasa-1:4, Mesalamine Enema; Drug
Lead sponsor: Altheus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 45
States / cities: Birmingham, Alabama • Dothan, Alabama • Lakewood, Colorado + 39 more

Conditions: Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
Interventions: low glycemic index (LGI) diet, high glycemic index (HGI) diet plus placebo (PLAC), high glycemic index diet plus N-acetylcysteine; Other · Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anosmia, Head Trauma
Interventions: N Acetyl Cysteine, Placebo oral capsule; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Nutriceutical formulation, Placebo; Dietary Supplement · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 40 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Naples, Florida • Baltimore, Maryland • Ayer, Massachusetts + 5 more

Conditions: Posttraumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), Substance Use Disorder (SUD)
Interventions: N-acetylcysteine, Placebo, Cognitive behavioral therapy; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Bipolar Disorder
Interventions: Aspirin, N-acetyl-cysteine (NAC), Sugar Pill; Drug · Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Bronchitis
Interventions: Oral N-acetycystein (NAC); Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Mood Disturbance, Mood Disorders, Natural Supplements, Alternative Treatment
Interventions: Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years to 17 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cannabis Dependence
Interventions: N-Acetylcysteine, placebo, Contingency Management; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 13 Years to 21 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
Interventions: Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D); Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Labor, Premature, Preterm Premature Rupture of the Membranes, Infection, Inflammation, Chorioamnionitis
Interventions: amniocentesis, N-acetylcysteine or placebo; Procedure · Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 2
States / cities: New Haven, Connecticut • Columbus, Ohio

Conditions: Covid-19
Interventions: N-acetylcysteine, Peripheral Blood; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder, Alcohol Use Disorder
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Acetaminophen Toxicity
Interventions: Not listed
Lead sponsor: Akron Children's Hospital; Other
Eligibility: Not listed
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Neurofibromatosis 1
Interventions: N-acetylcysteine (NAC), Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 16 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pathologic Skin Picking, Neurotic Excoriation, Psychogenic Excoriation, Dermatillomania
Interventions: N-Acetyl Cysteine, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cognitive Dysfunction
Interventions: N-acetylcysteine and ketamine, placebo and ketamine; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Myeloproliferative Neoplasm, MPN, Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis
Interventions: N-Acetylcysteine; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Irvine, California • Orange, California

Conditions: Ameliorating Oxidative Stress in Type 1 Diabetes
Interventions: N-acetyl cysteine, omega 6 Fish oil ( PUFA), Placebo; Drug · Dietary Supplement
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma, COPD
Interventions: n-acetylcystine (NAC)+ albuterol, AeroEclipse-VersaPAP System; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Gaucher Disease Type 1
Interventions: N-acetylcysteine; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Nephropathy
Interventions: Oral N-Acetylcysteine, Sodium Bicarbonate; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

Effect of Dietary Glycemic Index on Beta-cell Function

NAC for Head Trauma-induced Anosmia

A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

NAC for Treating Comorbid PTSD and SUD

N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder

Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis

A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth

A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

N-acetylcysteine in Intra-amniotic Infection/Inflammation

A Study of N-acetylcysteine in Patients With COVID-19 Infection

N-Acetylcysteine for Bipolar and Alcohol Use Disorders

Treatment of Acetaminophen Toxicity With N-acetylcysteine

Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1

N-Acetyl Cysteine in Pathologic Skin Picking

N-acetylcysteine and NMDA Antagonist Interactions

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Antioxidant Use in Diabetes to Reduce Oxidative Stress

The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate